Inogen, Inc. INGN R2K

Q: What is the current share price of Inogen, Inc. (INGN)?

As of 2026-07-14 21:23 PDT, Inogen, Inc. (INGN) trades at $6.33 on NasdaqGS. Its 52-week range is $5.59 to $8.95.

Q: What is the market capitalisation of INGN?

Inogen, Inc. (INGN) has a market capitalisation of $171.38M on NasdaqGS.

Q: What is the P/E ratio of INGN?

INGN trades at a trailing price-to-earnings (P/E) ratio of -6.96. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.96.

Q: What is the return on equity (ROE) of INGN?

INGN has a return on equity (ROE) of -13.07%. Its return on capital employed (ROCE) is -12.85%.

Q: Is INGN a good stock to buy?

This page provides a data-driven analysis of Inogen, Inc. (INGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.provider.inogen.com

Company Profile ↓

$6.33

-5.66% 1Y

Mkt Cap$171.38M

P/E-6.96

P/B0.96

52W High$8.95

52W Low$5.59

Book Value$6.68

EPS (TTM)$-0.91

Company Overview

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 14.9% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Recent Developments

Dec 2025 Revenue of $295.30M (+5.9% YoY); net profit $-22.75M.
Trailing 12 Months Year-on-year growth — revenue +3.4%.
5-Year Trend Long-term compounding — revenue CAGR 14.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	14.89%
1 Year:	3.40%

Stock Price Performance

1 Year:	-5.66%
6 Months:	-9.96%
3 Months:	-1.86%
1 Month:	+0.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 22% of range

$5.59 $8.95

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)43.11 · Neutral

Price Performance

1M+0.48%

3M-1.86%

6M-9.96%

1Y-5.66%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 14.9% over 5 years.

CONS

Trading 29.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-6.96

Industry PE

25.41

Forward P/E

-24.35

PEG Ratio

Book Value

$6.68

Price to Book

0.96

P/S

0.49

EV/EBITDA

-9.08

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

14.89%

Profit 5Y

Revenue (YoY)

3.40%

Earnings (YoY)

Profitability & Returns

ROCE

-12.85%

ROE

-13.07%

ROA

-6.14%

Profit Margin

-7.08%

Op Margin

-9.89%

Gross Margin

44.31%

EPS (Latest Qtr)

$-0.30

EPS (TTM)

$-0.91

Balance Sheet & Liquidity

Debt/Equity

0.09

Quick Ratio

2.47

Current Ratio

3.10

Debt

$16.93M

Total Assets

$285.93M

Current Assets

Working Capital

Ownership

Promoter Holding

12.64%

Chg in Prom Hold

FII / Inst Holding

77.28%

Chg in FII Hold

-0.52%

Financial Snapshot

Enterprise Value

$171.38M

Total Revenue (TTM)

$351.50M

EBITDA

$-8.81M

Free Cash Flow

$-2.41M

Operating Cash Flow

$-1.11M

Shares Outstanding

27.07M

Gross Margin

44.31%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INGN Inogen, Inc. R2K	6.33	-6.96	$171.38M	0.00%	-12.85%	-13.07%	14.89%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	58.04M	63.14M	-	73.58M	91.99M	89.71M	-	84.82M	95.86M	86.39M	-	83.14M	65.61M	66.81M	-	77.08M	90.30M	80.97M	67.40M	89.29M	90.67M	55.89M	68.34M	67.97M	63.09M	74.42M	74.93M	68.47M	79.17M	79.09M	72.40M
Gross Profit	16.02M	20.82M	19.38M	20.04M	21.28M	26.21M	25.13M	24.69M	25.74M	31.57M	33.17M	30.76M	37.73M	48.47M	48.81M	43.57M	44.41M	50.22M	43.31M	33.92M	38.37M	32.75M	33.01M	34.06M	39.87M	50.34M	47.69M	35.01M	46.26M	42.80M	30.73M	34.04M	33.76M	34.37M	42.74M	41.34M	36.37M	41.34M	41.32M	37.86M
Operating Income	2.52M	5.34M	3.71M	-	3.28M	8.02M	5.40M	-	5.57M	8.50M	8.33M	-	8.70M	14.02M	10.40M	-	4.86M	12.14M	8.11M	-	-2.18M	-2.35M	-1.97M	-	-2.13M	11.67M	6.37M	-13.59M	-2.88M	-10.29M	-21.91M	-11.77M	-46.72M	-16.27M	-7.06M	-7.79M	-7.66M	-6.13M	-7.12M	-9.34M
Net Income	1.57M	3.46M	2.70M	3.86M	2.52M	7.49M	5.25M	5.26M	5.93M	8.34M	7.34M	-606.00K	10.76M	14.61M	16.43M	10.04M	5.30M	10.16M	6.86M	-1.38M	-1.59M	2.58M	-1.70M	-5.12M	-732.00K	5.10M	12.17M	-14.21M	-3.44M	-9.51M	-20.35M	-9.83M	-45.72M	-14.58M	-5.59M	-5.96M	-6.17M	-4.15M	-5.29M	-8.32M
Diluted EPS	0.08	0.17	0.13	0.19	0.12	0.36	0.25	0.25	0.27	0.38	0.33	-0.03	0.48	0.65	0.73	0.44	0.24	0.45	0.31	-0.06	-0.07	0.12	-0.08	-0.23	-0.03	0.22	0.53	-0.62	-0.15	-0.42	-0.88	-0.42	-1.97	-0.62	-0.24	-0.25	-0.25	-0.15	-0.20	-0.30
R&D Expense	863.00K	975.00K	1.12M	-	1.17M	1.38M	1.35M	-	1.31M	1.26M	1.38M	-	1.42M	1.77M	2.10M	-	1.67M	1.47M	2.64M	-	3.60M	3.29M	3.51M	-	4.01M	4.12M	3.75M	5.36M	6.06M	4.58M	5.34M	4.29M	4.49M	6.58M	5.62M	3.52M	4.03M	5.21M	4.84M	5.10M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	48.58M	75.44M	112.54M	159.00M	168.17M	225.49M	336.01M	340.55M	280.19M	311.73M	320.55M	251.61M	278.76M	295.30M
Gross Profit	23.95M	38.99M	55.52M	76.26M	97.31M	121.24M	178.58M	171.86M	138.18M	176.48M	153.53M	126.70M	154.74M	154.26M
Operating Income	829.00K	4.46M	10.51M	15.05M	22.86M	27.59M	37.89M	19.79M	-12.03M	9.24M	-85.24M	-109.39M	-42.52M	-30.21M
Net Income	564.00K	25.43M	6.83M	11.59M	20.52M	21.00M	51.84M	20.95M	-5.83M	-6.33M	-83.77M	-102.45M	-35.89M	-22.75M
Diluted EPS	-19.97	0.68	0.30	0.56	0.97	0.96	2.30	0.94	-0.27	-0.28	-3.67	-4.42	-1.52	-0.86
R&D Expense	2.26M	2.40M	2.98M	4.18M	5.11M	5.31M	7.03M	9.40M	14.08M	16.58M	21.94M	20.84M	21.61M	19.40M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	82.40M	140.09M	161.31M	180.78M	197.52M	211.31M	214.05M	275.07M	375.90M	447.34M	461.85M	489.51M	405.04M	326.19M	296.19M	298.62M
Total Equity	-75.57M	-80.77M	-62.37M	118.15M	134.02M	150.57M	162.24M	172.60M	182.09M	227.04M	310.42M	344.62M	349.62M	370.23M	297.41M	204.81M	173.86M	192.23M
Cash & Equivalents	3.91M	15.11M	13.52M	56.84M	66.11M	-	-	-	92.85M	142.95M	196.63M	198.04M	211.96M	235.52M	187.01M	125.49M	113.80M	103.73M
Long Term Debt	-	-	5.39M	315.00K	315.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	26.10M	21.93M	27.30M	-	-	-	31.96M	48.03M	65.47M	102.72M	112.23M	119.29M	107.64M	121.38M	122.33M	106.39M
Current Liabilities	-	-	18.83M	18.73M	22.01M	-	-	-	22.84M	33.89M	46.59M	50.18M	56.71M	61.51M	65.35M	72.50M	76.69M	63.53M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	31.03M	60.49M	59.98M	40.59M	37.01M	23.63M	-37.53M	-3.23M	5.91M	-11.22M
Investing Cash Flow	-	-	-	-	-11.93M	-24.43M	-24.96M	-44.06M	-25.64M	-14.64M	-10.88M	-59.31M	-13.97M	-26.21M
Financing Cash Flow	-	-	-	-	7.71M	14.00M	18.30M	4.93M	2.07M	15.00M	380.00K	960.00K	265.00K	24.18M
Capital Expenditure	-2.02M	-3.03M	-1.55M	-2.21M	-1.72M	-2.91M	-8.04M	-3.14M	-4.38M	-5.48M	-3.34M	-5.22M	-3.36M	-2.52M
Free Cash Flow	-	-	-	-	29.32M	57.58M	51.93M	37.45M	32.63M	18.15M	-40.87M	-8.45M	2.55M	-13.74M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	49.3%	51.7%	49.3%	48.0%	57.9%	53.8%	53.1%	50.5%	49.3%	56.6%	47.9%	50.4%	55.5%	52.2%
Operating Margin %	1.7%	5.9%	9.3%	9.5%	13.6%	12.2%	11.3%	5.8%	-4.3%	3.0%	-26.6%	-43.5%	-15.3%	-10.2%
Net Margin %	1.2%	33.7%	6.1%	7.3%	12.2%	9.3%	15.4%	6.2%	-2.1%	-2.0%	-26.1%	-40.7%	-12.9%	-7.7%
ROE %	-0.7%	-40.8%	5.8%	8.6%	11.3%	9.3%	16.7%	6.1%	-1.7%	-1.7%	-28.2%	-50.0%	-20.6%	-11.8%
ROCE %	-	7.0%	8.7%	10.8%	12.0%	11.4%	11.5%	5.0%	-3.0%	2.2%	-25.1%	-43.1%	-19.4%	-12.8%

Shareholding Pattern

Insiders

12.64%

Institutions

77.28%

Public Float

88.46%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.08%	1.65M	$10.97M
2	Armistice Capital, LLC	4.43%	1.20M	$7.99M
3	Acadian Asset Management. LLC	4.00%	1.08M	$7.22M
4	Vanguard Capital Management LLC	3.83%	1.04M	$6.90M
5	Ameriprise Financial, Inc.	3.17%	859.54K	$5.72M
6	DAFNA Capital Management, LLC	3.12%	845.18K	$5.63M
7	Point72 Asset Management, L.P.	2.37%	642.37K	$4.28M
8	Geode Capital Management, LLC	2.27%	613.53K	$4.09M
9	Arrowstreet Capital, Limited Partnership	2.16%	586.16K	$3.90M
10	Goldman Sachs Group Inc	2.14%	580.10K	$3.86M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INGN

Google News hu, 09 Jul 2026

Inogen (INGN) EVP, COO awarded 130,000 restricted stock units vesting from 2026 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPeUd2Y0hoQzRBbE5RUWxDRkVDNDRyc0VUeDVWUC1LZXJCMzFwMkk5c0RNdGlnZnMwdWlvTDR0dFpxTXk4cDhHTVdFTTZYRDZaLUVkSXFVRGZLZ2E5ckFENmxBNXpyWHJDRGRlM0dOVEY5WjFjQnVaeDY3VUk1SUVSc056S0NZY3R2MmJZdE…

Google News Sat, 11 Jul 2026

Understanding the Setup: (INGN) and Scalable Risk - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPN21YWW5TeUhZZlFaOG1Xd3pET3JZZlFhVGdRWUtfeE9TQ2NRWTZ2NFlHZE9HLUdoUjdVTkJSUDFCNURJb2FYcHlodE5LdldzVFdwRWRhRldWak1nQnE4T19weHNHcC12SXVvMHpiWFBISC0zRzhIZG9maE9ldXdheDRCMmNkMUxxTTVwQW…

Google News hu, 25 Jun 2026

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQUml4dHo1blVfRWVLSUR4OGpmNVVqREYxaURTYlZPMTcyWHhIdTlGY205dGdfcnJBQnR3dnRFaExwWDMwZXBHSFJyc01LWHlTeWRhNmd6N0lTeEZqRnlXLVNtUkF3T2hTNm1feC0yRzVNbmhaeXhrX3lFNlVWUG9zMTJ2VGhxbEFJRklLZF…

Google News hu, 02 Jul 2026

Inogen Appoints New Chief Operating Officer for Growth - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZmpOS2l0QjBCQUR5ckVDQld5dUtsQUpnOXFSZW1oV3ZRNVFmMkY1VUxGN042WWRJLUh6eVhVMzRObFZqd1lXUU1rci1NYVd3c0diLXo1SGM3QW9aNlFBb2g0emRhcU0zckE3Uy1VbnNEcmVTaEtJRnB4RXlPRzRFMEZPWGpEQ2pPRmRSOE…

Google News hu, 15 Jan 2026

Inogen (NASDAQ:INGN shareholders incur further losses as stock declines 11% this week, taking five-year losses to 86% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOU0x2ZEhUU0U0czJsbHVqeVJUZTVLbEpEc3lHdEdzbUU2djJIYzFiejBMVG05WEUzLXlWQ0xfU0hKajh2QWVWQVdoWEtCRzJNZFVOcGN0UWlhbUlCallySW00V29lbkd2Qkc5S2QwT3VoUkhDMnhCdmoxd2FQMWxDX2YxZW5FYzB0bGxCQz…

Google News hu, 09 Jul 2026

Inogen (INGN) EVP, COO Andrew Reding files baseline Form 3 insider report - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOclN1ZkNyZW51ZERVMUFTX0tReXllRDRWV3NRTkstbFBsZHF2NDRxYUM5Q0JQOTZvV2l5amxoX0cyRWdubUJ5X0FOaFNuaTZadktqYTZKa1NrVVpOMmlGR2lza0ZqZXhYNGxoN2FzWjdpeDNld2t2WTRneVBvcGRrWU5rVk4waks5LXNKRk…

INGN — Frequently Asked Questions

What is the current share price of Inogen, Inc. (INGN)?

As of 2026-07-14 21:23 PDT, Inogen, Inc. (INGN) trades at $6.33 on NasdaqGS. Its 52-week range is $5.59 to $8.95.

What is the market capitalisation of INGN?

Inogen, Inc. (INGN) has a market capitalisation of $171.38M on NasdaqGS.

What is the P/E ratio of INGN?

INGN trades at a trailing price-to-earnings (P/E) ratio of -6.96. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.96.

What is the return on equity (ROE) of INGN?

INGN has a return on equity (ROE) of -13.07%. Its return on capital employed (ROCE) is -12.85%.

Is INGN a good stock to buy?

This page provides a data-driven analysis of Inogen, Inc. (INGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Inogen, Inc. INGN R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Inogen (INGN) EVP, COO awarded 130,000 restricted stock units vesting from 2026 - Stock Titan

Understanding the Setup: (INGN) and Scalable Risk - Stock Traders Daily

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now - Yahoo Finance

Inogen Appoints New Chief Operating Officer for Growth - The Globe and Mail

Inogen (NASDAQ:INGN shareholders incur further losses as stock declines 11% this week, taking five-year losses to 86% - simplywall.st

Inogen (INGN) EVP, COO Andrew Reding files baseline Form 3 insider report - Stock Titan

INGN — Frequently Asked Questions

What is the current share price of Inogen, Inc. (INGN)?

What is the market capitalisation of INGN?

What is the P/E ratio of INGN?

What is the return on equity (ROE) of INGN?

Is INGN a good stock to buy?

Explore More